Skip to main content
SpringerLink
Log in

Medical Management of Head and Face Pain

  • Chapter
  • First Online:
Diagnosis and Management of Head and Face Pain

  • 1115 Accesses

Abstract

No longer regarded as a potent, universal remedy for all pain, opiates have fallen out of favor in the most recent pain literature. Increases in addiction, rising overdose deaths, systemic side effects, and the discovery of opiate-induced hyperalgesia have illuminated the need for non-opiate alternatives for all chronic pain disorders. During this chapter we will explore the literature behind many of these alternative, non-opiate medications and their use for nonmalignant pain of the head and neck.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ambrosio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024*. Neurochem Res. 2002;27(1):121–30.

    Article  CAS  PubMed  Google Scholar 

  2. Blom S. Tic douloureux treated with new anticonvulsant. Experiences with G32883. Arch Neurol. 1963;9:285–90.

    Article  CAS  PubMed  Google Scholar 

  3. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1966;29(3):265–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol. 1966;15(2):129–36.

    Article  PubMed  CAS  Google Scholar 

  5. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 1968;19(2):129–36.

    Article  PubMed  CAS  Google Scholar 

  6. Nicol CF. A four year double-blind study of tegretol in facial pain. Headache. 1969;9(1):54–7.

    Article  PubMed  CAS  Google Scholar 

  7. Cruccu G, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–28.

    Article  CAS  PubMed  Google Scholar 

  8. Micromedex Drug Reference Essentials App; 2017; micromedex.com/mobile.

    Google Scholar 

  9. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311:1047–52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Wiffen P, Collins S, Carroll D, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;(3):CD001133.

    Google Scholar 

  11. Wiffen P, McQuay H, Moore R. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev. 2005;(3):CD005451.

    Google Scholar 

  12. Dougherty JA, Rhoney DH. Gabapentin: a unique anti-epileptic agent. Neurol Res. 2001;23:821–9.

    Article  PubMed  CAS  Google Scholar 

  13. Errante LD, Williamson A, Spencer DD, Petroff OAC. Gabapentin and vigabatrin increase GABA in the human neocortical slice. Epilepsy Res. 2002;49:203–10.

    Article  PubMed  CAS  Google Scholar 

  14. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol. 1996;39:95–9.

    Article  CAS  PubMed  Google Scholar 

  15. Whitworth TL, Quick MW. Upregulation of γ-aminobutyric acid transporter expression: role of alkylated γ-aminobutyric acid derivatives. Biochem Soc Trans. 2001;29:736–41.

    Article  CAS  PubMed  Google Scholar 

  16. Freiman TM, Kukolja J, Heinemeyer J, Eckhardt K, Aranda H, Rominger A, Dooley DJ, Zentner J, Feuerstein TJ. Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin: involvement of KATP channels. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:537–42.

    Article  CAS  PubMed  Google Scholar 

  17. Jaggi AS, Singh N. Role of different brain areas in peripheral nerve injury-induced neuropathic pain. Brain Res. 2011;1381:187–201.

    Article  CAS  PubMed  Google Scholar 

  18. Jarvis SE, Zamponi GW. Trafficking and regulation of neuronal voltage gated calcium channels. Curr Opin Cell Biol. 2007;19:474–82.

    Article  CAS  PubMed  Google Scholar 

  19. Morimoto S, Ito M, Oda S, Sugiyama A, Kuroda M, Adachi-Akahane S. Spinal mechanism underlying the antiallodynic effect of gabapentin studied in the mouse spinal nerve ligation model. J Pharmacol Sci. 2012;118:455–66.

    Article  CAS  PubMed  Google Scholar 

  20. Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain. 2006;7(1 Suppl 1):S13–30.

    Article  PubMed  CAS  Google Scholar 

  21. Taylor CP. The biology and pharmacology of α2-δ proteins. CNS Drug Rev. 2004;10:183–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kukkar A, Bali A, Singh N, et al. Arch Pharm Res. 2013;36:237.

    Article  PubMed  CAS  Google Scholar 

  23. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice ASC. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(4):CD007938.

    Google Scholar 

  24. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology. 1998;51:611.

    Article  PubMed  CAS  Google Scholar 

  25. Solaro C, Lunardi GL, Capello E. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology. 1998;51:609–11.

    Article  PubMed  CAS  Google Scholar 

  26. Solaro C, Messmer Uccelli M, et al. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44:45–8.

    Article  PubMed  CAS  Google Scholar 

  27. Rozen TD. Relief of anesthesia dolorosa with gabapentin. Headache. 1999;39:761.

    Article  PubMed  CAS  Google Scholar 

  28. Sawada T, Asai J, Nomiyama T, Masuda K, Takenaka H, Katoh N. Trigeminal trophic syndrome: report of a case and review of the published work. J Dermatol. 2014;41:525–8.

    Article  PubMed  Google Scholar 

  29. White TL, Kent PF, Kurtz DB, Emko P. Effectiveness of gabapentin for treatment of burning mouth syndrome. Arch Otolaryngol Head Neck Sug. 2004;130:786–8.

    Article  Google Scholar 

  30. Heckmann SM, Heckman JG, Ungethum A, Hujoel P, Hummel T. Gabapentin has little or no effect in the treatment of burning mouth syndrome—results of an open-label pilot study. Eur J Neurol. 2006;13:e6–7.

    Article  PubMed  CAS  Google Scholar 

  31. López-D’Alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of burning mouth syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal. 2011;16(5):e635–40.

    Article  PubMed  Google Scholar 

  32. Li Z, et al. Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel subunits. Eur J Pharmacol. 2001;667:80–90.

    Article  CAS  Google Scholar 

  33. Lotarski SM, et al. Anxiolytic-like activity of pregabalin in the Vogel conflict test in α2δ-1 (R217A) and α2δ-2 (R279A) mouse mutants. J Pharmacol Exp Ther. 2011;338:615–21.

    Article  PubMed  CAS  Google Scholar 

  34. Dolphin AC. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond. Nat Rev Neurosci. 2012;13:542–55.

    Article  PubMed  CAS  Google Scholar 

  35. Tuchman M, et al. Central sensitization and Ca(V)α2δ ligands in chronic pain syndromes: pathologic processes and pharmacologic effect. J Pain. 2010;11:1241–9.

    Article  PubMed  CAS  Google Scholar 

  36. Bauer CS, et al. The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo. Biochem Soc Trans. 2010;38:525–8.

    Article  PubMed  Google Scholar 

  37. Takeuchi Y, et al. Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology. 2007;53:842–53.

    Article  PubMed  CAS  Google Scholar 

  38. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274.

    Article  PubMed  CAS  Google Scholar 

  39. Sabatowski R, Gálvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109(1–2):26.

    Article  PubMed  CAS  Google Scholar 

  40. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076.

    Google Scholar 

  41. Tunnicliff G. Basis of the antiseizure action of phenytoin. Gen Pharmacol. 1996;27(7):1091–7.

    Article  PubMed  CAS  Google Scholar 

  42. Patejdl R, Leroux AC, Noack T. Phenytoin inhibits contractions of rat gastrointestinal and portal vein smooth muscle by inhibiting calcium entry. Neurogastroenterol Motil. 2015;27(10):1453–65.

    Article  PubMed  CAS  Google Scholar 

  43. Colombo E, Franceschetti S, Avanzini G, Mantegazza M. Phenytoin inhibits the persistent sodium current in neocortical neurons by modifying its inactivation properties. PLoS One. 2013;8(1):e55329.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Thorn CF, Whirl-Carrillo M, Leeder JS, Klein TE, Altman RB. Phar-mGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012;22(6):466–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Bergouignan M. Cures heureuses de nevralgies faciales essentielles par le diphenylhydantoinate de soude. Rev Laryngol Otol Rhinol. 1942;63:34–41.

    Google Scholar 

  46. Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India. 1978;26(5):403–6.

    PubMed  CAS  Google Scholar 

  47. Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther. 1977;22(2):196–9.

    Article  PubMed  CAS  Google Scholar 

  48. McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg. 1999;89(4):985–8.

    PubMed  CAS  Google Scholar 

  49. Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;(5):CD009485.

    Google Scholar 

  50. Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol. 2009;89:176–92.

    Article  CAS  PubMed  Google Scholar 

  51. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(a)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42:210–20.

    Article  CAS  PubMed  Google Scholar 

  52. Sun GC, Werkman TR, Battefeld A, Clare JJ, Wadman WJ. Carbamazepine and topiramate modulation of transient and persistent sodium currents studied in HEK293 cells expressing the Na(v)1.3 alpha-subunit. Epilepsia. 2007;48:774–82.

    Article  PubMed  CAS  Google Scholar 

  53. Kuzmiski JB, Barr W, Zamponi GW, MacVicar BA. Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. Epilepsia. 2005;46:481–9.

    Article  PubMed  CAS  Google Scholar 

  54. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41:S10–6.

    Article  CAS  Google Scholar 

  55. Poulsen CF, Simeone TA, Maar TE, Smith-Swintosky V, White HS, Schousboe A. Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem Res. 2004;29:275–82.

    Article  PubMed  CAS  Google Scholar 

  56. Braga MFM, Aroniadou-Anderjaska V, Li H, Rogawski MA. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAa receptors on principal neurons. J Pharmacol Exp Ther. 2009;330:558–66.

    Article  PubMed  CAS  Google Scholar 

  57. Kanda T, Kurokawa M, Tamura S, et al. Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci. 1996;59:1607–16.

    Article  PubMed  CAS  Google Scholar 

  58. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet. 2010;376(9741):645–55.

    Article  PubMed  CAS  Google Scholar 

  59. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965.

    Article  PubMed  CAS  Google Scholar 

  60. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490.

    Article  PubMed  Google Scholar 

  61. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010610.

    Google Scholar 

  62. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010611.

    Google Scholar 

  63. Silberstein SD, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults (Report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society). Neurology. 2012;78:1337–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55:1587–8.

    Article  CAS  PubMed  Google Scholar 

  65. Domingues RB, Kuster GW, Aquino CC. Treatment of trigeminal neuralgia with low dose topiramate. Arq Neuropsiquiatr. 2007;65(3B):792–4.

    Article  PubMed  Google Scholar 

  66. Wang QP, Bai M. Topiramate versus carbamazepine for the treatment of classical trigeminal neuralgia: a meta-analysis. CNS Drugs. 2011;25:847–57.

    Article  CAS  PubMed  Google Scholar 

  67. Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia: the pharmacological and surgical options. Neurosciences. 2015;20(2):107–14.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Volcy M, Rapoport AM, Tepper SJ, et al. Persistent idiopathic facial pain responsive to topiramate. Cephalalgia. 2006;26:489.

    Article  CAS  PubMed  Google Scholar 

  69. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med. 2008;9:175–85.

    Article  PubMed  Google Scholar 

  70. Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017;57:165–78.

    Article  PubMed  Google Scholar 

  71. Silberstein SD, Saper J, Berenson F, Somogyi M, McCague K, D’Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008;70(7):548–55.

    Article  CAS  PubMed  Google Scholar 

  72. Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2010;(1):CD001133.

    Google Scholar 

  73. Toth M. The epsilon theory: a novel synthesis of the underlying molecular and electrophysiological mechanisms of primary generalized epilepsy and the possible mechanism of action of valproate. Med Hypotheses. 2005;64(2):267–72.

    Article  CAS  PubMed  Google Scholar 

  74. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997;17(2):93–100.

    Article  CAS  PubMed  Google Scholar 

  75. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.

    Google Scholar 

  76. Kochar DK, Garg P, Bumb RA, Kochar SK, Mehta RD, Beniwal R, et al. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. QJM. 2005;98(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  77. Kochar DK, Rawat N, Agrawal RP, Vyas A, Beniwal R, Kochar SK, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM. 2004;97(1):33–8.

    Article  CAS  PubMed  Google Scholar 

  78. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(10):CD009183.

    Google Scholar 

  79. Green GA. Understanding NSAIDs: from aspirin to Cox-2. Clin Cornerstone. 2001;3(5):50–60.

    Article  PubMed  CAS  Google Scholar 

  80. Brogan S, et al. Non-opiate analgesics. In: Hemmings H, Egan T, editors. Pharmacology and physiology for anesthesia: foundations and clinical application (Chapter 16). 1st ed. 2013. Saunders: Elsevier.

    Google Scholar 

  81. Minor J, Hofhines A. The discovery of aspirin’s antithrombotic effects. Tex Heart Inst J. 2007;34(2):179–86.

    Google Scholar 

  82. Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain. 2004;111(1–2):13–21.

    Article  CAS  PubMed  Google Scholar 

  83. Varoli F, et al. Analgesia evaluation of 2 NSAID drugs as adjuvant in management of chronic temporomandibular disorders. Sci World J. 2015;2015:359152.

    Google Scholar 

  84. Senye M, et al. Topical nonsteroidal anti-inflammatory medications for treatment of temporomandibular joint degenerative pain: a systematic review. J Orofac Pain. 2012;26(1):26–32.

    PubMed  Google Scholar 

  85. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized health problem. Arch Intern Med. 2000;160(6):777–84.

    Article  CAS  PubMed  Google Scholar 

  86. Barnes P. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Delecoeuillerie G, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens. Ann Rheum Dis. 1988;47(9):733–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1990;17(10):1340–5.

    PubMed  CAS  Google Scholar 

  89. Jivraj I, Tamhankar M. The treatment of giant cell arteritis. Curr Treat Options Neurol. 2017;19(1):2.

    Article  PubMed  Google Scholar 

  90. Beck RW, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The OpticNeuritis Study Group. N Engl J Med. 1992;326(9):581–8.

    Article  PubMed  CAS  Google Scholar 

  91. Sellebjerg F, et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999;52(7):1479–984.

    Article  PubMed  CAS  Google Scholar 

  92. Smith JL, Taxdal DS. Painful ophthalmoplegia. The Tolosa-Hunt syndrome. Am J Ophthalmol. 1966;61(6):1466–72.

    Article  PubMed  CAS  Google Scholar 

  93. Hannerz J. Recurrent Tolosa-Hunt syndrome. Cephalalgia. 1992;12(1):45–51.

    Article  PubMed  CAS  Google Scholar 

  94. Cakirer S. MRI findings in Tolosa-Hunt syndrome before and after systemic corticosteroid therapy. Eur J Radiol. 2003;45(2):83–90.

    Article  PubMed  Google Scholar 

  95. Zurawski J, Akhondi H. Tolosa-Hunt syndrome—a rare cause of headache and ophthalmoplegia. Lancet. 2013;382(9895):912.

    Article  PubMed  Google Scholar 

  96. Lal V, et al. Ophthalmoplegia with migraine in adults: is it ophthalmoplegic migraine? Headache. 2009;49(6):838–50.

    Article  PubMed  Google Scholar 

  97. Proven A, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Care Res. 2003;49(5):703–8.

    Article  CAS  Google Scholar 

  98. Fromm GH, et al. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol. 1984;15:240–4.

    Article  PubMed  CAS  Google Scholar 

  99. Yomiya K, et al. Baclofen as an adjuvant analgesic for cancer pain. Am J Hosp Palliat Med. 2009;26(2):112–8.

    Article  Google Scholar 

  100. Saper JR, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470–82.

    Article  PubMed  Google Scholar 

  101. Fogelholm R, Murros K. Tizanidine in chronic tension type headache: a placebo controlled double blind crossover study. Headache. 1992;32:509–13.

    Article  PubMed  CAS  Google Scholar 

  102. Freitag FG. Preventative treatment for migraine and tension-type headaches: do drugs having effects on muscle spasm and tone have a role? CNS Drugs. 2003;17(6):373–81.

    Article  PubMed  CAS  Google Scholar 

  103. Aiyer R, et al. Treatment of neuropathic pain with venlafaxine: a systematic review. Pain Med. 2016;18(10):1999–2012.

    Google Scholar 

  104. Smith HS, et al. Antidepressants as analgesics. In: Benzon H, Rathmell JP, editors. Practical management of pain (Chapter 38). 5th ed; 2014.

    Google Scholar 

  105. Nagashima W, et al. Effectiveness of duloxetine for the treatment of chronic nonorganic facial pain. Clin Neuropharmacol. 2012;35:273–7.

    Article  PubMed  CAS  Google Scholar 

  106. Ito M, et al. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol. 2010;33:79–83.

    Article  CAS  PubMed  Google Scholar 

  107. Derry S, et al. Nortriptyline for neuropathic pain in adults (review). Cochrane Database Syst Rev. 2015;(1):CD011209.

    Google Scholar 

  108. Pettengill CA, Reisner-Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. J Craniomandibular Pract. 1997;15(1):53–6.

    CAS  Google Scholar 

  109. Moore RA, et al. Amitriptyline for neuropathic pain in adults (review). Cochrane Database Syst Rev. 2015;(7):CD008242.

    Google Scholar 

  110. Krymchantowski AV, et al. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain. 2012;13:53–9.

    Article  PubMed  CAS  Google Scholar 

  111. Jeon SH, et al. Effects of nortriptyline on QT prolongation: a safety pharmacology study. Hum Exp Toxicol. 2011;30(10):1649–56.

    Article  CAS  PubMed  Google Scholar 

  112. Peppin JF, Albrecht PJ, Argoff C, et al. Skin matters: a review of topical treatments for chronic pain. Part Two: treatments and applications. Pain Therapy. 2015;4(1):33–50.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Mohammadkarimi N, Jafari M, Mellat A, Kazemi E, Shirali A. Evaluation of efficacy of intra-nasal lidocaine for headache relief in patients refer to emergency department. J Res Med Sci. 2014;19(4):331–5.

    PubMed  PubMed Central  CAS  Google Scholar 

  114. Robbins L. Intranasal lidocaine for cluster headache. Headache. 1995;35:83–4.

    Article  CAS  PubMed  Google Scholar 

  115. Costa A, Antonaci F, Ramusino MC, Nappi G. The neuropharmacology of cluster headache and other trigeminal autonomic cephalalgias. Curr Neuropharmacol. 2015;13(3):304–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  116. Kern K-U, Nalamachu S, Brasseur L, Zakrzewska JM. Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain? J Pain Res. 2013;6:261–80.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  117. Khawaja N, Yilmaz Z, Renton T. Case studies illustrating the management of trigeminal neuropathic pain using topical 5% lidocaine plasters. Br J Pain. 2013;7(2):107–13.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Medscape Mobile Application. Copyright WebMD, LLC, 1994-2016.

    Google Scholar 

  119. Marks DR, Rapoport A, Padla D, Weeks R, Rosum R, Sheftell F, Arrowsmith F. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia. 1993;13(2):114–6.

    Article  CAS  PubMed  Google Scholar 

  120. Matharu M. Cluster headache. BMJ Clin Evidence. 2010;2010:1212.

    Google Scholar 

  121. Szok D, Csáti A, Vécsei L, Tajti J. Treatment of chronic migraine with OnabotulinumtoxinA: mode of action, efficacy and safety. Toxins. 2015;7(7):2659–73. https://doi.org/10.3390/toxins7072659.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  122. Finkel AG. Botulinum toxin and the treatment of headache: a clinical review. Toxicon. 2015;107(Pt A):114–9. https://doi.org/10.1016/j.toxicon.2015.09.008.

    Article  PubMed  CAS  Google Scholar 

  123. Wang DW, Mistry AM, Kahlig KM, Kearney JA, Xiang J, George AL. Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front Pharmacol. 2010;1:144.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Negoro K. Calcium antagonists in the prophylactic treatment of migraine. Brain Nerve. 2009;61(10):1135–41.

    PubMed  CAS  Google Scholar 

  126. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. Br Med J. 2001;322(7277):19.

    Article  CAS  Google Scholar 

  127. Orr SL, Aubé M, Becker WJ, Davenport WJ, Dilli E, Dodick D, Giammarco R, Gladstone J, Leroux E, Pim H, Dickinson G, Christie SN. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35(3):271–84.

    Article  PubMed  Google Scholar 

  128. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  129. Greco R, Mangione AS, Sandrini G, Nappi G, Tassorelli C. Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain. 2014;15(1):14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  130. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4(1):245–59.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. Fine PG, Rosenfeld MJ. The Endocannabinoid System, cannabinoids, and pain. Eisenberg E, Vulfsons S, editors. Rambam Maimonides Med J. 2013;4(4):e0022. Cannabinoids in the management of difficult to treat pain.

    Google Scholar 

  132. Sativex Product Insert. http://www.medicines.org.uk/emc/medicine/23262#companyDetails

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Johnathan H. Goree & Christopher S. Fiedorek

  2. Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA

    Ruben G. Alexander & Boris Spektor

Authors
  1. Johnathan H. Goree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher S. Fiedorek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruben G. Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Boris Spektor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johnathan H. Goree .

Editor information

Editors and Affiliations

  1. Department of Otolaryngology-HNS, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    James Y. Suen

  2. Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    Erika Petersen

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Goree, J.H., Fiedorek, C.S., Alexander, R.G., Spektor, B. (2018). Medical Management of Head and Face Pain. In: Suen, J., Petersen, E. (eds) Diagnosis and Management of Head and Face Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-90999-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90999-8_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90998-1

  • Online ISBN: 978-3-319-90999-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation